KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eli Lilly (LLY) Receivables (2016 - 2025)

Historic Receivables for Eli Lilly (LLY) over the last 17 years, with Q4 2025 value amounting to $20.2 billion.

  • Eli Lilly's Receivables rose 5181.53% to $20.2 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $20.2 billion, marking a year-over-year increase of 5181.53%. This contributed to the annual value of $20.2 billion for FY2025, which is 5181.53% up from last year.
  • As of Q4 2025, Eli Lilly's Receivables stood at $20.2 billion, which was up 5181.53% from $19.5 billion recorded in Q3 2025.
  • In the past 5 years, Eli Lilly's Receivables registered a high of $20.2 billion during Q4 2025, and its lowest value of $6.7 billion during Q1 2021.
  • Its 5-year average for Receivables is $11.0 billion, with a median of $9.6 billion in 2023.
  • In the last 5 years, Eli Lilly's Receivables soared by 481.86% in 2021 and then surged by 6144.78% in 2025.
  • Quarter analysis of 5 years shows Eli Lilly's Receivables stood at $8.1 billion in 2021, then grew by 5.31% to $8.6 billion in 2022, then skyrocketed by 32.45% to $11.3 billion in 2023, then grew by 17.11% to $13.3 billion in 2024, then surged by 51.82% to $20.2 billion in 2025.
  • Its Receivables stands at $20.2 billion for Q4 2025, versus $19.5 billion for Q3 2025 and $17.2 billion for Q2 2025.